JP2010510784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510784A5 JP2010510784A5 JP2009538639A JP2009538639A JP2010510784A5 JP 2010510784 A5 JP2010510784 A5 JP 2010510784A5 JP 2009538639 A JP2009538639 A JP 2009538639A JP 2009538639 A JP2009538639 A JP 2009538639A JP 2010510784 A5 JP2010510784 A5 JP 2010510784A5
- Authority
- JP
- Japan
- Prior art keywords
- her3
- receptor
- antibody
- sample
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86124306P | 2006-11-28 | 2006-11-28 | |
| EP06024658 | 2006-11-28 | ||
| EP06024658.4 | 2006-11-28 | ||
| US60/861,243 | 2006-11-28 | ||
| PCT/EP2007/010335 WO2008064884A1 (en) | 2006-11-28 | 2007-11-28 | Activated her3 as a marker for predicting therapeutic efficacy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510784A JP2010510784A (ja) | 2010-04-08 |
| JP2010510784A5 true JP2010510784A5 (enExample) | 2011-01-20 |
| JP5656406B2 JP5656406B2 (ja) | 2015-01-21 |
Family
ID=38961070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538639A Active JP5656406B2 (ja) | 2006-11-28 | 2007-11-28 | 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100047829A1 (enExample) |
| EP (2) | EP2097754B2 (enExample) |
| JP (1) | JP5656406B2 (enExample) |
| AU (1) | AU2007324868B2 (enExample) |
| CA (1) | CA2670522C (enExample) |
| WO (1) | WO2008064884A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| NZ579644A (en) | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| NZ582618A (en) | 2007-07-13 | 2012-07-27 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| KR20110044905A (ko) | 2008-08-15 | 2011-05-02 | 메리맥 파마슈티컬즈, 인크. | 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템 |
| EP2352851A1 (en) | 2008-11-12 | 2011-08-10 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Use of erbb4 as a prognostic and therapeutic marker for melanoma |
| JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
| US20120270745A1 (en) * | 2009-07-15 | 2012-10-25 | Prometheus Laboratories Inc. | Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples |
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| US20110318336A1 (en) * | 2010-03-29 | 2011-12-29 | George Mason Intellectual Properties, Inc. | Identification and Treatment of Aggressive Lung Cancer Tumors |
| JP2013539453A (ja) | 2010-07-09 | 2013-10-24 | エクセリクシス， インク． | 癌の治療のためのキナーゼ阻害物質の組み合わせ |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
| ES2670651T3 (es) * | 2011-10-04 | 2018-05-31 | Expression Pathology, Inc. | Ensayo de SRM/MRM para determinar la proteína ERBB-4 del receptor de tirosina-proteína quinasa (HER4) |
| CN108424456B (zh) | 2011-11-23 | 2022-04-26 | 医学免疫有限责任公司 | 特异于her3的结合分子及其用途 |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| KR101524915B1 (ko) | 2013-05-10 | 2015-06-02 | 포항공과대학교 산학협력단 | 타이로신 인산화효소를 감지하는 형광 프로브 및 이의 용도 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5804396A (en) * | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| DK0896586T4 (en) | 1996-03-27 | 2015-08-24 | Genentech Inc | ErbB3 antibodies. |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| WO2002058450A2 (en) * | 2000-12-22 | 2002-08-01 | Dana-Faber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
| WO2003011897A1 (en) * | 2001-07-27 | 2003-02-13 | The Regents Of The University Of California | Modulation of heregulin and her3 interaction |
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| AU2003233576A1 (en) * | 2002-05-17 | 2003-12-02 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
| SI1509230T1 (sl) * | 2002-06-05 | 2007-06-30 | Cedars Sinai Medical Center | Gefitinib (iressa) za zdravljenje raka |
| ATE442589T1 (de) | 2002-07-25 | 2009-09-15 | Aclara Biosciences Inc | Nachweis der rezeptoroligomerisierung |
| BRPI0408928A (pt) | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
| WO2005049829A1 (en) * | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Process |
| JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
| WO2005011607A2 (en) * | 2003-08-01 | 2005-02-10 | Smithkline Beecham Corporation | Treatment of cancers expressing p95 erbb2 |
| JP5422120B2 (ja) * | 2004-05-27 | 2014-02-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法 |
| CA2587519A1 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| US20060204505A1 (en) * | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
-
2007
- 2007-11-28 WO PCT/EP2007/010335 patent/WO2008064884A1/en not_active Ceased
- 2007-11-28 AU AU2007324868A patent/AU2007324868B2/en active Active
- 2007-11-28 JP JP2009538639A patent/JP5656406B2/ja active Active
- 2007-11-28 US US12/516,682 patent/US20100047829A1/en not_active Abandoned
- 2007-11-28 EP EP07846863.4A patent/EP2097754B2/en active Active
- 2007-11-28 EP EP12176507A patent/EP2518508A1/en not_active Withdrawn
- 2007-11-28 CA CA2670522A patent/CA2670522C/en active Active
-
2016
- 2016-02-18 US US15/047,041 patent/US10365283B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qian et al. | Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma | |
| Morris et al. | HER‐2 profiling and targeting in prostate carcinoma: A Phase II trial of trastuzumab alone and with paclitaxel | |
| Gavine et al. | Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models | |
| JP5656406B2 (ja) | 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ | |
| Kazemi et al. | VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans | |
| Go et al. | Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma | |
| Schmitz et al. | Window of opportunity studies: do they fulfil our expectations? | |
| WO2005010486A3 (en) | Biomarker panel for colorectal cancer | |
| KR20140002711A (ko) | 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법 | |
| Lee et al. | Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab | |
| ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| Millanta et al. | Immunohistochemical expression of COX-2, mPGES and EP2 receptor in normal and reactive canine bone and in canine osteosarcoma | |
| Johnson et al. | Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma | |
| WO2013126147A2 (en) | Elevated psma identifies lethal prostate cancers | |
| JP2016517960A5 (enExample) | ||
| JP2016515141A5 (enExample) | ||
| JP2009516178A5 (enExample) | ||
| Ramsay et al. | Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy | |
| JP5413818B2 (ja) | 蛍光多重染色による蛋白定量法 | |
| Kossatz et al. | PARP1 as a biomarker for early detection and intraoperative tumor delineation in epithelial cancers–first-in-human results | |
| Überall et al. | Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer | |
| JP2011527575A5 (enExample) | ||
| RuizdelRio et al. | Profibrotic role of inducible heat shock protein 90α isoform in systemic sclerosis | |
| George | Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor | |
| CN103562722A (zh) | 一种区分甲状腺癌变的方法、实施该方法的试剂盒以及金属硫蛋白在区分甲状腺癌变中的用途 |